Shares of IceCure Medical Ltd (NASDAQ:ICCM - Get Free Report) were down 4.4% during trading on Monday . The company traded as low as $1.28 and last traded at $1.29. Approximately 202,105 shares traded hands during mid-day trading, a decline of 60% from the average daily volume of 508,000 shares. The stock had previously closed at $1.35.
Analysts Set New Price Targets
Separately, HC Wainwright reaffirmed a "buy" rating and set a $2.50 price target on shares of IceCure Medical in a report on Wednesday, November 27th.
Read Our Latest Analysis on IceCure Medical
IceCure Medical Stock Up 2.9 %
The company has a quick ratio of 2.27, a current ratio of 2.67 and a debt-to-equity ratio of 0.02. The firm has a 50 day moving average of $1.31 and a two-hundred day moving average of $0.94. The firm has a market capitalization of $78.81 million, a price-to-earnings ratio of -4.90 and a beta of 0.37.
Institutional Inflows and Outflows
A hedge fund recently raised its stake in IceCure Medical stock. Geode Capital Management LLC raised its holdings in IceCure Medical Ltd (NASDAQ:ICCM - Free Report) by 58.3% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 40,453 shares of the company's stock after purchasing an additional 14,893 shares during the period. Geode Capital Management LLC owned 0.07% of IceCure Medical worth $44,000 at the end of the most recent reporting period. 0.62% of the stock is currently owned by hedge funds and other institutional investors.
About IceCure Medical
(
Get Free Report)
IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors. The company offers ProSense system, a single probe system for the treatment of tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology.
Featured Articles
Before you consider IceCure Medical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IceCure Medical wasn't on the list.
While IceCure Medical currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
